<DOC>
	<DOCNO>NCT01837849</DOCNO>
	<brief_summary>To compare therapeutic efficacy recombinant human brain natriuretic peptide ( rhBNP ) dobutamine acute decompensated heart failure patient different blood BNP level</brief_summary>
	<brief_title>A Comparison Recombinant Human Brain Natriuretic Peptide Dobutamine</brief_title>
	<detailed_description>Patients acute decompensated heart failure ( ADHF ) whose leave ventricular ejection fraction ( LVEF ) &lt; 40 % , assign high BNP group ( BNP â‰¤ 3000 pg/mL ) extra-high BNP group ( BNP &gt; 3000 pg/mL ) , depend admission plasma BNP level . Each group subdivide rhBNP dobutamine subgroup accord intravenous administration either rhBNP dobutamine 24-72h . The effect rhBNP dobutamine patient high extra-high BNP group compare .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Dobutamine</mesh_term>
	<mesh_term>Natriuretic Peptide , Brain</mesh_term>
	<criteria>patient classify NYHA class IIIIV ejection fraction &lt; 40 % intravenous administration rhBNP dobutamine 2 week study entry acute myocardial infarction significant valvular stenosis serious ventricular arrhythmia ( frequent ventricular premature beat &gt; 5 bpm , nonsustained sustain ventricular tachycardia ) blood pressure &lt; 95/60 mmHg &gt; 140/90 mmHg shock hypovolemia hepatic renal impairment pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>heart failure</keyword>
	<keyword>rhBNP</keyword>
	<keyword>Dobutamine</keyword>
</DOC>